• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

寡转移前列腺癌的生物学特性：与多转移前列腺癌不同的“野兽”。

The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.

机构信息

Jewish General Hospital, Montreal, Canada.

Centre de Recherche en Cancérologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France.

出版信息

Eur Urol Focus. 2019 Mar;5(2):117-118. doi: 10.1016/j.euf.2018.11.011. Epub 2018 Dec 4.

DOI:10.1016/j.euf.2018.11.011
PMID:30527643
Abstract

The natural history and molecular biology of oligometastatic prostate cancer differentiate it from polymetastatic disease. Clinically, oligometastatic disease is also predictive and prognostic for different outcomes. Studies specific to this population are required to establish the benefits of intervention.

摘要

寡转移前列腺癌的自然史和分子生物学使其有别于多转移疾病。从临床角度来看，寡转移疾病也可以预测和预示不同的结局。需要针对这一人群进行专门的研究，以确定干预的益处。

相似文献

1
The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.寡转移前列腺癌的生物学特性：与多转移前列腺癌不同的“野兽”。
Eur Urol Focus. 2019 Mar;5(2):117-118. doi: 10.1016/j.euf.2018.11.011. Epub 2018 Dec 4.
2
The biology of prostate cancer metastases: does oligo differ from polymetastatic?前列腺癌转移的生物学特性：寡转移与多转移有何不同？
Curr Opin Urol. 2017 Nov;27(6):542-546. doi: 10.1097/MOU.0000000000000434.
3
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.寡转移前列腺癌与广泛转移疾病的生物学基础相同，应当进行差异化研究和治疗。反方观点：因此，它们不应进行差异化治疗。
Eur Urol Focus. 2019 Mar;5(2):119-122. doi: 10.1016/j.euf.2019.01.018. Epub 2019 Feb 23.
4
Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.发现和验证血清 microRNA 特征以表征寡转移和多转移前列腺癌：尚未准备好投入使用。
World J Urol. 2019 Dec;37(12):2557-2564. doi: 10.1007/s00345-018-2609-8. Epub 2018 Dec 21.
5
What Is Oligometastatic Prostate Cancer?寡转移前列腺癌是什么？
Eur Urol Focus. 2019 Mar;5(2):159-161. doi: 10.1016/j.euf.2018.12.009. Epub 2019 Jan 12.
6
Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.寡转移前列腺癌：借助分子成像及对肿瘤生物学的深入理解来界定其定义
Curr Opin Urol. 2017 Nov;27(6):533-541. doi: 10.1097/MOU.0000000000000449.
7
MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets.微小 RNA 介导的前列腺癌转移调控：对新型生物标志物和治疗靶点鉴定的启示。
Curr Med Chem. 2013;20(12):1566-84. doi: 10.2174/0929867311320120007.
8
MicroRNAs as Regulators of Prostate Cancer Metastasis.微小 RNA 作为前列腺癌转移的调控因子。
Adv Exp Med Biol. 2018;1095:83-100. doi: 10.1007/978-3-319-95693-0_5.
9
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.使用现代成像方法促进前列腺癌寡转移疾病转移导向治疗的临床试验：来自 EORTC 影像学组的共识建议。
Lancet Oncol. 2018 Oct;19(10):e534-e545. doi: 10.1016/S1470-2045(18)30571-0. Epub 2018 Oct 1.
10
Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).寡转移前列腺癌消融性放疗共识声明：意大利放射治疗和肿瘤临床学会（AIRO）立场文件。
Crit Rev Oncol Hematol. 2019 Jun;138:24-28. doi: 10.1016/j.critrevonc.2019.03.014. Epub 2019 Apr 1.

引用本文的文献

1
Metastasis-Directed Therapy in Oligometastatic Prostate Cancer: Biological Rationale and Systematic Review of Published Data.寡转移前列腺癌的转移导向治疗：生物学原理及已发表数据的系统综述
Cancers (Basel). 2025 Apr 8;17(8):1256. doi: 10.3390/cancers17081256.
2
From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine.从前列腺癌的分子机制到转化应用：基于多组学融合分析与智能医学
Health Inf Sci Syst. 2023 Dec 18;12(1):6. doi: 10.1007/s13755-023-00264-5. eCollection 2024 Dec.
3
Characteristics of Radiopharmaceutical Uptake in Primary Tumor and Metastatic Lesions of Prostate Carcinoma: Comparison of Oligometastatic with Multimetastatic Disease.
前列腺癌原发肿瘤及转移病灶中放射性药物摄取的特征：寡转移与多转移疾病的比较
Mol Imaging Radionucl Ther. 2023 Feb 23;32(1):20-27. doi: 10.4274/mirt.galenos.2022.71463.
4
Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.初诊或复发性寡转移前列腺癌原发灶和转移灶的局部治疗：现状与未来展望。
World J Urol. 2023 Aug;41(8):2077-2090. doi: 10.1007/s00345-022-04162-5. Epub 2022 Oct 2.
5
Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer.激素敏感性寡转移性前列腺癌治疗的最新进展
Cancer Manag Res. 2022 Jan 6;14:89-101. doi: 10.2147/CMAR.S321136. eCollection 2022.
6
Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review.探索用于寡转移前列腺癌特征描述的miRNA特征及其他潜在生物标志物：临床实践背后的生物学挑战。一篇叙述性综述。
Cancers (Basel). 2021 Jun 30;13(13):3278. doi: 10.3390/cancers13133278.
7
Competitive Advantage of PSMA Theranostics in Prostate Cancer.前列腺特异性膜抗原（PSMA）诊疗在前列腺癌中的竞争优势
Radiology. 2021 May;299(2):261-263. doi: 10.1148/radiol.2021210348. Epub 2021 Mar 30.